{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Ensysce Biosciences, Inc."},"Symbol":{"label":"Symbol","value":"ENSC"},"Address":{"label":"Address","value":"7946 IVANHOE AVENUE,SUITE 201, LA JOLLA, California, 92037, United States"},"Phone":{"label":"Phone","value":"+1 858 263-4196"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Ensysce's products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs."},"CompanyUrl":{"label":"Company Url","value":"https://www.ensysce.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"D. Lynn Kirkpatrick","title":"President, Chief Executive Officer & Director"},{"name":"Jeffrey Millard","title":"Chief Operating Officer"},{"name":"William K. Schmidt","title":"Chief Medical Officer & SVP-Clinical Development"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}